Maximo Agustin Schiavone: What Does ‘Risk-Factor-Free MI’ Really Mean in Practice?
Maximo Agustin Schiavone, Head of Clinical Research – Bariatric and Metabolic Surgery Department at Hospital Universitario Austral, shared a post on LinkedIn about a recent article by Daniel G. Brieger et al, published in Atherosclerosis:
“A ‘risk-factor-free’ heart attack is one of the most uncomfortable truths in preventive cardiology.
Because it exposes a category error we keep making: we treat risk factors as if they were the disease. But the disease is coronary atherosclerosis—and it can be present, active, and dangerous even when the usual checklist looks ‘clean.’
This review puts numbers on it: 14–25% of MI patients present without standard modifiable risk factors (SMuRFs), and SMuRFs explain only ~53–56% of incident CVD events globally. And the inequity signal is loud: SMuRF-less women with MI have nearly a threefold higher early mortality risk compared with men who have at least one risk factor.
So what does ‘risk-factor-free MI’ really mean in practice?
It often means ‘we missed the atherosclerosis’—because our prevention model is built to estimate risk, not to detect disease. The authors explicitly argue for moving beyond probability scores to directly detect the causal disease (atherosclerosis) before symptoms arise.
That framing matters: if you’re ‘SMuRF-less’ the correct clinical reflex shouldn’t be reassurance. It should be better phenotyping and a pathway that stops confusing ‘absence of classic risk factors’ with ‘absence of coronary disease.’
And yes, sex needs to be treated as a biological variable in the whole pipeline, because the performance gaps are most evident in women.”
Title: Coronary artery disease in the absence of standard modifiable risk factors (SMuRFs): The impact of sex
Authors: James Amamoo, Lin Xie, Andrea Steffens, Erin Buysman, Caroline Swift, Sherif Mehanna, Noelle N. Gronroos, Marc P. Bonaca
Read the Full Article on Atherosclerosis
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 20, 2026, 17:47Julie Rayes: Commenting on a Seminal NEJM Study Solving the Mystery of VITT
-
Mar 20, 2026, 17:45William Tembo: Advancing Stroke Care by Validating Acute Ischemic Treatment
-
Mar 20, 2026, 17:37Renjith Vijayakumar Selvarani: New Nanoparticle Approach Clears Brain Plaque and Restores Memory
-
Mar 20, 2026, 17:35Bawan Ahmed: New Evidence May Shift DOAC Choice in Acute DVT Management
-
Mar 20, 2026, 17:17Angelo Cascio Rizzo: CTA-Based Plaque RADS Improves Risk Stratification in ESUS
-
Mar 20, 2026, 17:09Clinical Practice Guidelines for Platelet Transfusion in Non-Surgical and Non-Traumatic Settings – CEBaP
-
Mar 20, 2026, 17:07The Rich Heterogeneity of Platelets and Its Vital Shifts Across Disease States – RPTH
-
Mar 20, 2026, 17:05Pierre Fontana: Launching the European Interuniversity Certificate in Clinical Haemostasis
-
Mar 20, 2026, 16:49Wolfgang Miesbach: A Pivotal Step Forward for Patients with von Willebrand Disease Across All Subtypes